BBH
VanEck Biotech ETF
BBH
VanEck Biotech ETF
-
NAV
$158.27
as of June 05, 2023 -
YTD RETURNS
-1.04%
as of June 05, 2023 -
Total Net Assets
$490.09M
as of June 05, 2023 -
Total Expense Ratio
0.35% -
Inception Date
12/20/2011
BBH Fees & Expenses: Van Eck Associates Corporation (the “Adviser”) will pay all expenses of the Fund, except for the fee payment under the investment management agreement, acquired fund fees and expenses, interest expense, offering costs, trading expenses, taxes and extraordinary expenses. Notwithstanding the foregoing, the Adviser has agreed to pay the offering costs until at least February 1, 2024. “Other Expenses” have been restated to reflect current fees.
Fund Description
VanEck Biotech ETF (BBH) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Biotech 25 Index (MVBBHTR), which is intended to track the overall performance of companies involved in the development and production, marketing and sales of drugs based on genetic analysis and diagnostic equipment.
Overview
Fund Highlights
- Highly Liquid Companies
Index seeks to track the most liquid companies in the industry based on market cap and trading volume
- Industry Leaders
Index methodology favors the largest companies in the industry
- Global Scope
Portfolio may include both domestic and U.S. listed foreign companies allowing for enhanced industry representation